Evolution of anti-HER2 therapies for cancer treatment

Cancer Treatment Reviews

Volumn 59, Issue , 2017, Pages 1-21

  Parakh, Sagun ^a,b,c   Gan, Hui K ^a,b,c   Parslow, Adam C ^a,c   Burvenich, Ingrid J G ^a,c   Burgess, Antony W ^d   Scott, Andrew M ^a,b,c,e  

^a OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

HER2; Imaging; Monoclonal antibodies; Pertuzumab; T DM1; Trastuzumab

Indexed keywords

AFATINIB; ANASTROZOLE; ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; LAPATINIB; LETROZOLE; MARGETUXIMAB; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PEMETREXED; PERTUZUMAB; PLACEBO; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VINORELBINE TARTRATE;

ADJUVANT THERAPY; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CARDIOTOXICITY; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM METASTASIS; COLORECTAL CANCER; CONFORMATIONAL TRANSITION; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG TARGETING; ENDOMETRIUM CARCINOMA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRIC CANCER; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL CANCER; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GASTROESOPHAGEAL JUNCTION CANCER; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; INFUSION RELATED REACTION; LUMINAL B BREAST CANCER; METASTATIC BREAST CANCER; METASTATIC COLORECTAL CANCER; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NON SMALL CELL LUNG CANCER; NONHUMAN; OLIGOMERIZATION; OVARY CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; REVIEW; SOLID MALIGNANT NEOPLASM; STOMACH ADENOCARCINOMA; STOMACH CANCER; UNSPECIFIED SIDE EFFECT; ADULT; AGED; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENETICS; MIDDLE AGED; MORTALITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES; PROGNOSIS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROGNOSIS; QUALITY OF LIFE; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 85023614553     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2017.06.005     Document Type: Review

References (311)

1. Olayioye, M.A., Neve, R.M., Lane, H.A., Hynes, N.E., The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:13 (2000), 3159–3167.
2. Reichelt, U., Duesedau, P., Tsourlakis, M.C., Quaas, A., Link, B.C., Schurr, P.G., et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 20:1 (2007), 120–129.
3. Gowryshankar, A., Nagaraja, V., Eslick, G.D., HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis. J Gastr Oncol 5:1 (2013), 25–35.
4. Nagaraja, V., Shaw, N., Morey, A., Cox, M., Eslick, G., HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: an Australian study. Eur J Surg Oncol (EJSO) 42:1 (2016), 140–148.
5. Burstein, H.J., The distinctive nature of HER2-positive breast cancers. N Engl J Med 353:16 (2005), 1652–1654.
6. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:4785 (1987), 177–182.
7. Tanner, M., Hollmen, M., Junttila, T., Kapanen, A., Tommola, S., Soini, Y., et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:2 (2005), 273–278.
8. Andrulis, I.L., Bull, S.B., Blackstein, M.E., Sutherland, D., Mak, C., Sidlofsky, S., et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16:4 (1998), 1340–1349.
9. Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Can Res 50:13 (1990), 4087–4091.
10. Tuefferd, M., Couturier, J., Penault-Llorca, F., Vincent-Salomon, A., Broët, P., Guastalla, J.-P., et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS ONE, 2(11), 2007, e1138.
11. Santin, A.D., Bellone, S., Van Stedum, S., Bushen, W., Palmieri, M., Siegel, E.R., et al. Amplification of c-erbB2 oncogene. Cancer 104:7 (2005), 1391–1397.
12. Morrison, C., Zanagnolo, V., Ramirez, N., Cohn, D.E., Kelbick, N., Copeland, L., et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24:15 (2006), 2376–2385.
13. Grushko, T., Filiaci, V., Mundt, A., Ridderstråle, K., Olopade, O., Fleming, G., An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 108:1 (2008), 3–9.
14. Liu, L., Shao, X., Gao, W., Bai, J., Wang, R., Huang, P., et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thoracic Oncol 5:12 (2010), 1922–1932.
15. Kristt, D.A., Yarden, Y., Differences between phosphotyrosine accumulation and Neu/ErbB-2 receptor expression in astrocytic proliferative processes: implications for glial oncogenesis. Cancer 78:6 (1996), 1272–1283.
16. Yonemura, Y., Ninomiya, I., Yamaguchi, A., Fushida, S., Kimura, H., Ohoyama, S., et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Can Res 51:3 (1991), 1034–1038.
17. Mineo, J.-F., Bordron, A., Baroncini, M., Maurage, C.-A., Ramirez, C., Siminski, R.-M., et al. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol 85:3 (2007), 281–287.
18. Santin, A.D., Bellone, S., Roman, J.J., McKenney, J.K., Pecorelli, S., Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynecol Obstet 102:2 (2008), 128–131.
19. Klapper, L.N., Glathe, S., Vaisman, N., Hynes, N.E., Andrews, G.C., Sela, M., et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci 96:9 (1999), 4995–5000.
20. Garrett, T.P., McKern, N.M., Lou, M., Elleman, T.C., Adams, T.E., Lovrecz, G.O., et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α. Cell 110:6 (2002), 763–773.
21. Cho, H.-S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney, D.W., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:6924 (2003), 756–760.
22. Maruyama, I.N., Mechanisms of activation of receptor tyrosine kinases: monomers or dimers. Cells 3:2 (2014), 304–330.
23. Wada, T., Qian, X., Greene, M.I., Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61:7 (1990), 1339–1347.
24. Sliwkowski, M.X., Schaefer, G., Akita, R.W., Lofgren, J.A., Fitzpatrick, V.D., Nuijens, A., et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 269:20 (1994), 14661–14665.
25. Karunagaran, D., Tzahar, E., Beerli, R.R., Chen, X., Graus-Porta, D., Ratzkin, B., et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J, 15(2), 1996, 254.
26. Lenferink, A.E., Pinkas-Kramarski, R., van de Poll, M.L., van Vugt, M.J., Klapper, L.N., Tzahar, E., et al. Differential endocytic routing of homo-and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 17:12 (1998), 3385–3397.
27. Huang, G., Chantry, A., Epstein, R.J., Overexpression of ErbB2 impairs ligand-dependent downregulation of epidermal growth factor receptors via a post-transcriptional mechanism. J Cell Biochem 74:1 (1999), 23–30.
28. Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:10 (1996), 5276–5287.
29. Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J, 15(10), 1996, 2452.
30. Sak, M.M., Szymanska, M., Bertelsen, V., Hasmann, M., Madshus, I.H., Stang, E., Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3. Carcinogenesis 34:9 (2013), 2031–2038.
31. Hudziak, R.M., Schlessinger, J., Ullrich, A., Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci 84:20 (1987), 7159–7163.
32. Chazin, V., Kaleko, M., Miller, A., Slamon, D., Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7:9 (1992), 1859–1866.
33. Ignatoski, K.M.W., Grewal, N.K., Markwart, S., Livant, D.L., Ethier, S.P., P38MAPK induces cell surface α 4 integrin downregulation to facilitate erbB-2-mediated invasion. Neoplasia 5:2 (2003), 128–134.
34. Benz, C.C., Scott, G.K., Sarup, J.C., Johnson, R.M., Tripathy, D., Coronado, E., et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:2 (1992), 85–95.
35. Wolf-Yadlin, A., Kumar, N., Zhang, Y., Hautaniemi, S., Zaman, M., Kim, H.D., et al. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol, 2(1), 2006.
36. Hendriks, B.S., Opresko, L.K., Wiley, H.S., Lauffenburger, D., Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis distribution of homo-AND heterodimers depends on relative HER2 levels. J Biol Chem 278:26 (2003), 23343–23351.
37. Albanell, J., Baselga, J., Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs Today (Barc) 35:12 (1999), 931–946.
38. Ko, B.-K., Lee, S.-Y., Lee, Y.-H., Hwang, I.-S., Persson, H., Rockberg, J., et al. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer. Mol Oncol 9:2 (2015), 398–408.
39. Mahdavi, M., Keyhanfar, M., Jafarian, A., Mohabatkar, H., Rabbani, M., Production and characterization of new anti-HER2 monoclonal antibodies. Monoclon Antib Immunodiagn Immunother 34:3 (2015), 213–221.
40. Ceran, C., Cokol, M., Cingoz, S., Tasan, I., Ozturk, M., Yagci, T., Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α. BMC Cancer, 12(1), 2012, 450.
41. Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F.J., Sahin, A.A., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:2 (2004), 117–127.
42. Clynes, R.A., Towers, T.L., Presta, L.G., Ravetch, J.V., Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:4 (2000), 443–446.
43. Shak S, editor. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Seminars in oncology; 1999.
44. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C.C., Dantis, L., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:3 (1996), 737–744.
45. Cobleigh, M.A., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., Fehrenbacher, L., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17(9), 1999, 2639.
46. Pegram, M.D., Lipton, A., Hayes, D.F., Weber, B.L., Baselga, J.M., Tripathy, D., et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:8 (1998), 2659–2671.
47. Balduzzi, S., Mantarro, S., Guarneri, V., Tagliabue, L., Pistotti, V., Moja, L., et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev, 6, 2014.
48. Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:11 (2001), 783–792.
49. Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:19 (2005), 4265–4274.
50. Kaufman, B., Mackey, J.R., Clemens, M.R., Bapsy, P.P., Vaid, A., Wardley, A., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2–positive, hormone receptor–positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27:33 (2009), 5529–5537.
51. Huober, J., Fasching, P., Barsoum, M., Petruzelka, L., Wallwiener, D., Thomssen, C., et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer–results of the eLEcTRA trial. Breast 21:1 (2012), 27–33.
52. Gasparini, G., Gion, M., Mariani, L., Papaldo, P., Crivellari, D., Filippelli, G., et al. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 101:3 (2007), 355–365.
53. Blackwell, K.L., Burstein, H.J., Storniolo, A.M., Rugo, H., Sledge, G., Koehler, M., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:7 (2010), 1124–1130.
54. von Minckwitz, G., Du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F.E., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2–positive advanced breast cancer: a German Breast Group 26/Breast International Group 03–05 study. J Clin Oncol 27:12 (2009), 1999–2006.
55. Osoba, D., Slamon, D.J., Burchmore, M., Murphy, M., Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 20:14 (2002), 3106–3113.
56. Rugo, H., Brammer, M., Zhang, F., Lalla, D., Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clin Breast Cancer 10:4 (2010), 288–293.
57. Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:9742 (2010), 687–697.
58. Zinner, R.G., Glisson, B.S., Fossella, F.V., Pisters, K.M., Kies, M.S., Lee, P.M., et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 44:1 (2004), 99–110.
59. Langer, C.J., Stephenson, P., Thor, A., Vangel, M., Johnson, D.H., Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 22:7 (2004), 1180–1187.
60. Gatzemeier, U., Groth, G., Butts, C., Van Zandwijk, N., Shepherd, F., Ardizzoni, A., et al. Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15:1 (2004), 19–27.
61. Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:2 (2002), 92–98.
62. Bookman, M.A., Darcy, K.M., Clarke-Pearson, D., Boothby, R.A., Horowitz, I.R., Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21:2 (2003), 283–290.
63. Fleming, G.F., Sill, M.W., Darcy, K.M., McMeekin, D.S., Thigpen, J.T., Adler, L.M., et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 116:1 (2010), 15–20.
64. Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 17:6 (2016), 738–746.
65. Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J., Wolmark, N., et al. Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC). Can Res 72:24 Supplement (2012), S1–S11.
66. Untch, M., Fasching, P.A., Konecny, G.E., Hasmüller, S., Lebeau, A., Kreienberg, R., et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2–overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:25 (2011), 3351–3357.
67. Esserman, L.J., Berry, D.A., DeMichele, A., Carey, L., Davis, S.E., Buxton, M., et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657. J Clin Oncol 30:26 (2012), 3242–3249.
68. Petrelli, F., Borgonovo, K., Cabiddu, M., Ghilardi, M., Barni, S., Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials. Anticancer Drugs 22:2 (2011), 128–135.
69. Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V., et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev, 4, 2012.
70. Pivot, X., Romieu, G., Debled, M., Pierga, J.-Y., Kerbrat, P., Bachelot, T., et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 14:8 (2013), 741–748.
71. Rivera F, Jimenez P, Garcia Alfonso P, Lopez C, Gallego J, Limon ML, et al., editors. NeoHx study: perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma–R0 resection, pCR, and toxicity analysis. ASCO annual meeting proceedings; 2013.
72. Hofheinz R, Hegewisch-Becker S, Thuss-Patience PC, Kunzmann V, Fuchs M, Graeven U, et al., editors. HER-FLOT: trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: a phase II trial of the AIO Gastric Cancer Study Group. ASCO annual meeting proceedings; 2014.
73. Abali H, Yalcin S, Onal HC, Dane F, Oksuzoglu B, Ozdemir N, et al., editors. A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2 + gastric or gastro-esophageal junction cancer (TOXAG study). ASCO annual meeting proceedings; 2016.
74. Adams, C.W., Allison, D.E., Flagella, K., Presta, L., Clarke, J., Dybdal, N., et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55:6 (2006), 717–727.
75. Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu–positive metastatic breast cancer. J Clin Oncol 26:11 (2008), 1789–1796.
76. Agus, D.B., Gordon, M.S., Taylor, C., Natale, R.B., Karlan, B., Mendelson, D.S., et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:11 (2005), 2534–2543.
77. Yamamoto, N., Yamada, Y., Fujiwara, Y., Yamada, K., Fujisaka, Y., Shimizu, T., et al. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol, 2009.
78. Agus, D.B., Sweeney, C.J., Morris, M.J., Mendelson, D.S., McNeel, D.G., Ahmann, F.R., et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 25:6 (2007), 675–681.
79. de Bono, J.S., Bellmunt, J., Attard, G., Droz, J.P., Miller, K., Flechon, A., et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 25:3 (2007), 257–262.
80. Herbst, R.S., Davies, A.M., Natale, R.B., Dang, T.P., Schiller, J.H., Garland, L.L., et al. Efficacy and safety of single-agent Pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non-small cell lung cancer. Clin Cancer Res 13:20 (2007), 6175–6181.
81. Gordon, M.S., Matei, D., Aghajanian, C., Matulonis, U.A., Brewer, M., Fleming, G.F., et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24:26 (2006), 4324–4332.
82. Baselga, J., Gelmon, K.A., Verma, S., Wardley, A., Conte, P., Miles, D., et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:7 (2010), 1138–1144.
83. Cortés, J., Fumoleau, P., Bianchi, G.V., Petrella, T.M., Gelmon, K., Pivot, X., et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol 30:14 (2012), 1594–1600.
84. Swain, S.M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:8 (2015), 724–734.
85. Cortés, J., Baselga, J., Im, Y.-H., Im, S.-A., Pivot, X., Ross, G., et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol 24:10 (2013), 2630–2635.
86. Kang, Y., Rha, S., Tassone, P., Barriuso, J., Yu, R., Szado, T., et al. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br J Cancer 111:4 (2014), 660–666.
87. Tabernero J, Hoff PM, Shen L, Ohtsu A, Yu R, Eng-Wong J, et al., editors. Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: an international phase III study (JACOB). J Clin Oncol; 2013: AMER SOC CLINICAL ONCOLOGY 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA.
88. Hughes, B., Mileshkin, L., Townley, P., Gitlitz, B., Eaton, K., Mitchell, P., et al. Pertuzumab and Erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging. Oncologist 19:2 (2014), 175–176.
89. Makhija, S., Amler, L.C., Glenn, D., Ueland, F.R., Gold, M.A., Dizon, D.S., et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 28:7 (2010), 1215–1223.
90. Kaye S, Poole C, Dańska-Bidzińska A, Gianni L, Del Conte G, Gorbunova V, et al. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Ann Oncol 2012:mds282.
91. González-Martín, A., Pautier, P., Mahner, S., Rau, J., Colombo, N., Ottevanger, P., et al. Pertuzumab plus chemotherapy for platinum-resistant ovarian cancer: safety run-in results of the PENELOPE trial. Int J Gynecol Cancer 26:5 (2016), 898–905.
92. Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:1 (2012), 25–32.
93. Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:9 (2013), 2278–2284.
94. Vogel, C.L., Cobleigh, M.A., Tripathy, D., Gutheil, J.C., Harris, L.N., Fehrenbacher, L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:3 (2002), 719–726.
95. Spector, N.L., Blackwell, K.L., Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol 27:34 (2009), 5838–5847.
96. Ritter, C.A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J.A., et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13:16 (2007), 4909–4919.
97. Klos, K.S., Zhou, X., Lee, S., Zhang, L., Yang, W., Nagata, Y., et al. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 98:7 (2003), 1377–1385.
98. O'Brien, N.A., Browne, B.C., Chow, L., Wang, Y., Ginther, C., Arboleda, J., et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 9:6 (2010), 1489–1502.
99. Yakes, F.M., Chinratanalab, W., Ritter, C.A., King, W., Seelig, S., Arteaga, C.L., Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Can Res 62:14 (2002), 4132–4141.
100. Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., Pollak, M., Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:24 (2001), 1852–1857.
101. Garrett, J.T., Arteaga, C.L., Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther 11:9 (2011), 793–800.
102. Nahta, R., Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance. Curr Med Chem 19:7 (2012), 1065–1075.
103. Nagy, P., Friedländer, E., Tanner, M., Kapanen, A.I., Carraway, K.L., Isola, J., et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Can Res 65:2 (2005), 473–482.
104. Ghedini, G.C., Ciravolo, V., Tortoreto, M., Giuffrè, S., Bianchi, F., Campiglio, M., et al. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility. J Cell Physiol 225:1 (2010), 256–265.
105. Kawaguchi, Y., Kono, K., Mizukami, Y., Mimura, K., Fujii, H., Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: relation to susceptibility to perforin-granzyme. Anticancer Res 29:6 (2009), 2137–2146.
106. Fujita, N., Sato, S., Katayama, K., Tsuruo, T., Akt-dependent phosphorylation of p27Kip1promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 277:32 (2002), 28706–28713.
107. Nahta, R., Takahashi, T., Ueno, N.T., Hung, M.-C., Esteva, F.J., P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells. Can Res 64:11 (2004), 3981–3986.
108. Santin, A.D., Letter to the Editor referring to the manuscript entitled: “Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study” recently reported by Fleming et al., (Gynecol Oncol., 116; 15–20; 2010). Gynecol Oncol 118:1 (2010), 95–96.
109. Wuerkenbieke, D., Wang, J., Li, Y., Ma, C., MiRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation. Arch Gynecol Obstet 292:5 (2015), 1109–1116.
110. Baselga, J., Cortés, J., Im, S.-A., Clark, E., Ross, G., Kiermaier, A., et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2–positive, first-line metastatic breast cancer. J Clin Oncol 32:33 (2014), 3753–3761.
111. Guarneri, V., Dieci, M.V., Frassoldati, A., Maiorana, A., Ficarra, G., Bettelli, S., et al. Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer. Oncologist 20:9 (2015), 1001–1010.
112. Diaz-Serrano A, Lopez-Rios F, Dominguez C, Fonseca PJ, Angulo B, Pazo Cid RA, et al., editors. PI3K upregulation as a negative predictive factor of survival in HER2 amplified gastric cancer treated with Trastuzumab. ASCO annual meeting proceedings; 2016.
113. Cizkova, M., Susini, A., Vacher, S., Cizeron-Clairac, G., Andrieu, C., Driouch, K., et al. PIK3CA mutation impact on survival in breast cancer patients and in ERa, PR and ERBB2-based subgroups. Breast Cancer Res, 14(1), 2012, R28.
114. Kalinsky, K., Jacks, L.M., Heguy, A., Patil, S., Drobnjak, M., Bhanot, U.K., et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15:16 (2009), 5049–5059.
115. Baselga J, Phillips GDL, Verma S, Ro J, Huober J, Guardino E, et al. Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin Cancer Res; 2016:clincanres. 2499.015.
116. Kim, S.B., Wildiers, H., Krop, I.E., Smitt, M., Yu, R., Lysbet de Haas, S., et al. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. Int J Cancer 139:10 (2016), 2336–2342.
117. Loibl, S., Majewski, I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer–pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol, 2016 mdw197.
118. André, F., O'Regan, R., Ozguroglu, M., Toi, M., Xu, B., Jerusalem, G., et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:6 (2014), 580–591.
119. Ni, J., Ramkissoon, S.H., Xie, S., Goel, S., Stover, D.G., Guo, H., et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med, 2016.
120. Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30:22 (2012), 2718–2724.
121. Yardley, D.A., Noguchi, S., Pritchard, K.I., Burris, H.A. III, Baselga, J., Gnant, M., et al. Everolimus plus exemestane in postmenopausal patients with HR + breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30:10 (2013), 870–884.
122. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer. J Clin Oncol 2013;JCO. 2012.44. 9694.
123. Wolff, A.C., Lazar, A.A., Bondarenko, I., Garin, A.M., Brincat, S., Chow, L., et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 31:2 (2013), 195–202.
124. Health UNIo. ClinicalTrials.gov; 2012.
125. Tevaarwerk, A.J., Kolesar, J.M., Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 31 (2009), 2332–2348.
126. Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:34 (2008), 4702–4711.
127. Cameron, D., Casey, M., Press, M., Lindquist, D., Pienkowski, T., Romieu, C.G., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:3 (2008), 533–543.
128. Geyer, C.E., Forster, J., Lindquist, D., Chan, S., Romieu, C.G., Pienkowski, T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:26 (2006), 2733–2743.
129. Cameron, D., Casey, M., Oliva, C., Newstat, B., Imwalle, B., Geyer, C.E., Lapatinib plus capecitabine in women with HER-2–positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15:9 (2010), 924–934.
130. Sherrill, B., Amonkar, M.M., Sherif, B., Maltzman, J., O'Rourke, L., Johnston, S., Quality of life in hormone receptor–positive HER-2 + metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist 15:9 (2010), 944–953.
131. Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor–positive metastatic breast cancer. J Clin Oncol 27:33 (2009), 5538–5546.
132. Blackwell, K.L., Burstein, H.J., Storniolo, A.M., Rugo, H.S., Sledge, G., Aktan, G., et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2–positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 30:21 (2012), 2585–2592.
133. Lin, N.U., Carey, L.A., Liu, M.C., Younger, J., Come, S.E., Ewend, M., et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol 26:12 (2008), 1993–1999.
134. Lin, N.U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:4 (2009), 1452–1459.
135. Hecht JR, Bang Y-J, Qin S, Chung H-C, Xu J-M, Park JO, et al., editors. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): the TRIO-013/LOGiC trial. ASCO annual meeting proceedings; 2013.
136. Satoh T, Xu R-H, Chung HC, Sun G-P, Doi T, Xu J-M, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study. J Clin Oncol 2014;JCO. 2013.53. 6136.
137. Janjigian, Y.Y., Lapatinib in gastric cancer: what is the LOGiCal next step?. J Clin Oncol, 2015 JCO642892.
138. Harbeck, N., Huang, C.-S., Hurvitz, S., Yeh, D.-C., Shao, Z., Im, S.-A., et al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol, 2016.
139. Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, et al. Abstract P5-19-07: randomized phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3. Cancer Res 2015;75(9 Supplement):P5–19-07-P5-19-07.
140. Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:9816 (2012), 633–640.
141. Guarneri, V., Frassoldati, A., Bottini, A., Cagossi, K., Bisagni, G., Sarti, S., et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2–positive operable breast cancer: results of the randomized phase II CHER-LOB Study. J Clin Oncol 30:16 (2012), 1989–1995.
142. Robidoux, A., Tang, G., Rastogi, P., Geyer, C.E., Azar, C.A., Atkins, J.N., et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 14:12 (2013), 1183–1192.
143. Carey LA, Berry DA, Ollila D, Harris L, Krop IE, Weckstein D, et al., editors. Clinical and translational results of CALGB 40601: a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. ASCO annual meeting proceedings; 2013.
144. Hicks, M., Macrae, E.R., Abdel-Rasoul, M., Layman, R., Friedman, S., Querry, J., et al. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials. Oncologist 20:4 (2015), 337–343.
145. De Azambuja, E., Holmes, A.P., Piccart-Gebhart, M., Holmes, E., Di Cosimo, S., Swaby, R.F., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 15:10 (2014), 1137–1146.
146. Piccart-Gebhart, M., Holmes, E., Baselga, J., de Azambuja, E., Dueck, A.C., Viale, G., et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2–positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol, 2015 JCO621797.
147. Goss, P.E., Smith, I.E., O'Shaughnessy, J., Ejlertsen, B., Kaufmann, M., Boyle, F., et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 14:1 (2013), 88–96.
148. Trowe, T., Boukouvala, S., Calkins, K., Cutler, R.E., Fong, R., Funke, R., et al. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res 14:8 (2008), 2465–2475.
149. Avizienyte, E., Ward, R.A., Garner, A.P., Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochem J 415:2 (2008), 197–206.
150. Eichhorn, P.J., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Can Res 68:22 (2008), 9221–9230.
151. Du, G., Bian, L., Wang, T., Xu, X., Zhang, S., Guo, Y., et al. PTEN loss correlates with the clinical efficacy of lapatinib in HER2 positive metastatic breast cancer with trastuzumab-resistance. Zhonghua yi xue za zhi 95:28 (2015), 2264–2267.
152. Zhang, X., Park, J.S., Park, K.H., Kim, K.H., Jung, M., Chung, H.C., et al. PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. Oncology 88:2 (2014), 76–85.
153. Luo, M., Fu, L.-W., Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors. Am J Cancer Res 4:6 (2014), 608–628.
154. Liu, L., Greger, J., Shi, H., Liu, Y., Greshock, J., Annan, R., et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 69:17 (2009), 6871–6878.
155. Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci 103:20 (2006), 7795–7800.
156. Li, Z., Yang, S.S., Yin, P.H., Chang, T., Shi, L.X., Fang, L., et al. Activated estrogen receptor-mitogen-activated protein kinases cross talk confer acquired resistance to lapatinib. Thoracic Cancer 6:6 (2015), 695–703.
157. Junttila, T.T., Li, G., Parsons, K., Phillips, G.L., Sliwkowski, M.X., Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128:2 (2011), 347–356.
158. Phillips, G.D.L., Li, G., Dugger, D.L., Crocker, L.M., Parsons, K.L., Mai, E., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate. Can Res 68:22 (2008), 9280–9290.
159. Barok, M., Tanner, M., Koninki, K., Isola, J., Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res, 13(2), 2011, R46.
160. Barok, M., Tanner, M., Köninki, K., Isola, J., Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 306:2 (2011), 171–179.
161. Verma, S., Miles, D., Gianni, L., Krop, I.E., Welslau, M., Baselga, J., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:19 (2012), 1783–1791.
162. Krop, I.E., Kim, S.-B., González-Martín, A., LoRusso, P.M., Ferrero, J.-M., Smitt, M., et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15:7 (2014), 689–699.
163. Ellis PA, Barrios CH, Eiermann W, Toi M, Im Y-H, Conte PF, et al., editors. Phase III, randomized study of trastuzumab emtansine (T-DM1){+/−} pertuzumab (P) vs. trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study. ASCO annual meeting proceedings; 2015.
164. Kang Y-K, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, van der Horst T, et al., editors. A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). ASCO annual meeting proceedings; 2016.
165. Mazières, J., Barlesi, F., Filleron, T., Besse, B., Monnet, I., Beau-Faller, M., et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol, 2015 mdv573.
166. Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang C-S, Thompson AM, et al., editors. Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K])+ pertuzumab (P) vs. docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC)(KRISTINE). ASCO annual meeting proceedings; 2016.
167. Tan, X., Jin, G., Myers, J., Diesl, V., Follettie, M., Lam, M.-H., et al. Tumor cells selected for resistance to an antibody-drug conjugate retain sensitivity to ADCs with modified linkers and payloads. Can Res, 73(8 Supplement), 2013, 4629.
168. Li, G., Fields, C., Parsons, K., Guo, J., Phillips, G.L., 223 Trastuzumab-DM1: mechanisms of action and mechanisms of resistance. Eur J Cancer Suppl, 8(7), 2010, 73.
169. Burris, H.A., Rugo, H.S., Vukelja, S.J., Vogel, C.L., Borson, R.A., Limentani, S., et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)–positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:4 (2011), 398–405.
170. Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Trans Med, 3(99), 2011 99ra86-99ra86.
171. Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1:6 (2011), 508–523.
172. Nadri, M., Soukhtanloo, M., Jafarian, A.H., Alamdari, M., Sisakhti, M., Kianoush, T., et al. Production and characterization of monoclonal antibodies against the dimerization domain of human HER2. Avicenna J Med Biochem, 3(2), 2015.
173. Tahmasebi, F., Kazemi, T., Amiri, M.M., Khoshnoodi, J., Mahmoudian, J., Bayat, A.A., et al. In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells. Immunotherapy 6:1 (2014), 43–49.
174. Higgins M, Gabrail N, Miller K, Agresta S, Sharma S, McDonagh C, et al., editors. A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer. J Clin Oncol; 2011: AMER SOC CLINICAL ONCOLOGY 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA.
175. Zhang, B., Lahdenranta, J., Du, J., Kirouac, D., Nguyen, S., Overland, R., et al. MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and paclitaxel in preclinical models of gastric cancer. Can Res, 73(8 Supplement), 2013, 4633.
176. Calvo E, Alsina M, Schellens JH, Huitema AD, Tabernero J, de Vries-Schultink A, et al. Abstract CT050: a phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors. AACR; 2016.
177. Alsina M, Boni V, Schellens JH, Moreno V, Bol K, Westendorp M, et al. First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: final phase 1 data and preliminary activity in HER2 + metastatic breast cancer (MBC). Am Soc Clin Oncol; 2017.
178. Wermke, M., Schmidt, H., Ochsenreither, S., Back, J., Salhi, Y., Bayever, E., 52TiPA phase 1 study of GBR 1302 in subjects with HER2-positive cancers. Ann Oncol, 27(suppl 8), 2016 mdw525. 52.
179. Moretti P, Macoin J, Croset A, Skregro D, Ollier R, Blein S, et al. A novel bispecific antibody for HER2 + breast cancer: the BEAT GBR 1302; 2016.
180. Meric-Bernstam F, Beeram M, Blum MA, Hausman DF, Infante JR, Patnaik A, et al. Phase 1 dose escalation of ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers. Am Soc Clin Oncol; 2017.
181. Stish, B., Oh, S., Chen, H., Dudek, A., Kratzke, R., Vallera, D., Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer 101:7 (2009), 1114–1123.
182. Nordstrom, J.L., Gorlatov, S., Zhang, W., Yang, Y., Huang, L., Burke, S., et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res, 13(6), 2011, 1.
183. Burris HA, Giaccone G, Im S-A, Bauer TM, Trepel JB, Nordstrom JL, et al., editors. Phase I study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody (MAb), in patients (pts) with advanced solid tumors expressing the HER2 oncoprotein. JOURNAL OF CLINICAL ONCOLOGY; 2013: AMER SOC CLINICAL ONCOLOGY 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA.
184. Pegram MD, Tan-Chiu E, Miller K, Rugo HS, Yardley DA, Liv S, et al., editors. A single-arm, open-label, phase 2 study of MGAH22 (margetuximab)[fc-optimized chimeric anti-HER2 monoclonal antibody (mAb)] in patients with relapsed or refractory advanced breast cancer whose tumors express HER2 at the 2 + level by immunohistochemistry and lack evidence of HER2 gene amplification by FISH. ASCO annual meeting proceedings; 2014.
185. Espelin, C.W., Leonard, S.C., Geretti, E., Wickham, T.J., Hendriks, B.S., Dual HER2 targeting with trastuzumab and liposomal-encapsulated doxorubicin (MM-302) demonstrates synergistic antitumor activity in breast and gastric cancer. Can Res 76:6 (2016), 1517–1527.
186. LoRusso, P., Krop, I., Miller, K., Ma, C., Siegel, B.A., Shields, A.F., et al. Abstract CT234: a phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2 + metastatic breast cancer. Can Res, 75(15 Supplement), 2015 CT234-CT.
187. Miller, K., Cortes, J., Huvitz, S.A., Krop, I.E., Tripathy, D., Verma, S., et al. HERMIONE: a phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline Naïve HER2-positive, locally advanced/metastatic breast cancer patients, previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1). J Clin Oncol, 33(Suppl), 2015 Abstract TPS641.
188. Dokter, W., Ubink, R., van der Lee, M., van der Vleuten, M., van Achterberg, T., Jacobs, D., et al. Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform. Mol Cancer Ther 13:11 (2014), 2618–2629.
189. Verheijden G, Beusker P, Ubink R, van der Lee M, Groothuis P, Goedings PJ, et al., editors. Toward clinical development of SYD985, a novel HER2-targeting antibody-drug conjugate (ADC). ASCO annual meeting proceedings; 2014.
190. Van Herpen C, Banerji U, Mommers E, Koper N, Goedings P, Lopez J, et al., editors. Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985. Eur J Cancer; 2015: ELSEVIER SCI LTD THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND.
191. Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 22:20 (2016), 5097–5108.
192. Iwata TN, Ishii C, Ogitani Y, Wada T, Agatsuma T. DS-8201a, a HER2-targeting antibody-drug conjugate, to elicit immune responses and benefits in combination with an anti-PD-1 antibody. Am Soc Clin Oncol; 2017.
193. Tamura, K., Shitara, K., Naito, Y., Shimomura, A., Fujiwara, Y., Yonemori, K., et al. Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: phase 1 dose escalation. Ann Oncol, 27(suppl_6), 2016.
194. Doi T, Iwata H, Tsurutani J, Takahashi S, Park H, Redfern CH, et al. Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors. Am Soc Clin Oncol; 2017.
195. Bergstrom, D., Bodyak, N., Park, P., Yurkovetskiy, A., DeVit, M., Yin, M., et al. Abstract P4-14-28: XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer. Can Res, 76(4 Supplement), 2016 P4-14-28-P4-14-28.
196. Bodyak N, Yurkovetskiy A, Gumerov DR, Xiao D, Thomas JDTD, Poling LL, et al. Optimization of lead antibody selection for XMT-1522, a novel, highly potent HER2-targeted antibody-drug conjugate (ADC). AACR; 2016.
197. Burris HA, Barve MA, Hamilton EP, Bardia A, Soliman HH, Jarlenski D, et al. A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2. Am Soc Clin Oncol; 2017.
198. Zhang, H., Wang, Y., Wu, Y., Jiang, X., Tao, Y., Yao, Y., et al. Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer. Signal Trans Targeted Ther, 2, 2017, 17015.
199. Bellati, F., Napoletano, C., Ruscito, I., Liberati, M., Panici, P.B., Nuti, M., Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy. J Clin Oncol, 28(21), 2010 e369-e70.
200. Jaime-Ramirez, A.C., Mundy-Bosse, B.L., Kondadasula, S., Jones, N.B., Roda, J.M., Mani, A., et al. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J Immunol 186:6 (2011), 3401–3409.
201. Perez, S.A., Karamouzis, M.V., Skarlos, D.V., Ardavanis, A., Sotiriadou, N.N., Iliopoulou, E.G., et al. CD4 + CD25 + regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res 13:9 (2007), 2714–2721.
202. Salgado, R., Denkert, C., Campbell, C., Savas, P., Nuciforo, P., Aura, C., et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO Trial. JAMA Oncol 1:4 (2015), 448–455.
203. Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B.M., Komor, M., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:1 (2010), 105–113.
204. Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25:8 (2014), 1544–1550.
205. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013;JCO. 2011.41. 0902.
206. Adams, S., Gray, R.J., Demaria, S., Goldstein, L., Perez, E.A., Shulman, L.N., et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:27 (2014), 2959–2966.
207. Stagg, J., Loi, S., Divisekera, U., Ngiow, S.F., Duret, H., Yagita, H., et al. Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci 108:17 (2011), 7142–7147.
208. Mittendorf, E., Clifton, G., Holmes, J., Schneble, E., van Echo, D., Ponniah, S., et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol, 2014 mdu211.
209. Trappey F, Berry JS, Vreeland TJ, Hale DF, Sears AK, Ponniah S, et al., editors. Randomized phase II clinical trial of the anti-HER2 (GP2) vaccine to prevent recurrence in high-risk breast cancer patients: a planned interim analysis. ASCO annual meeting proceedings; 2013.
210. Mittendorf EA, Perez SA, Hale DF, Vreeland TJ, Sears AK, Clifton GT, et al., editors. Early efficacy analysis of the AE37 vaccine in patients with HER2 low-expressing and triple-negative breast cancer. ASCO annual meeting proceedings; 2012.
211. Benavides, L.C., Sears, A.K., Gates, J.D., Clifton, G.T., Clive, K.S., Carmichael, M.G., et al. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. Expert Rev Vaccines 10:2 (2011), 201–210.
212. Mittendorf, E.A., Storrer, C.E., Shriver, C.D., Ponniah, S., Peoples, G.E., Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol 13:8 (2006), 1085–1098.
213. Sun, M., Shi, H., Liu, C., Liu, J., Liu, X., Sun, Y., Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Breast Cancer Res, 16(3), 2014, R61.
214. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 2015;JCO. 2014.58. 0225.
215. Rabindran, S.K., Discafani, C.M., Rosfjord, E.C., Baxter, M., Floyd, M.B., Golas, J., et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Can Res 64:11 (2004), 3958–3965.
216. Canonici, A., Gijsen, M., Mullooly, M., Bennett, R., Bouguern, N., Pedersen, K., et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget 4:10 (2013), 1592–1605.
217. Zhao, X.-q., Xie, J.-d., Chen, X.-g., Sim, H.M., Zhang, X., Liang, Y.-j., et al. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. Mol Pharmacol 82:1 (2012), 47–58.
218. Nafi, S., Generali, D., Kramer-Marek, G., Gijsen, M., Strina, C., Cappelletti, M., et al. Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget 5:15 (2014), 5934–5949.
219. Chan, A., Delaloge, S., Holmes, F.A., Moy, B., Iwata, H., Harvey, V.J., et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 2016.
220. Moulder-Thompson S, Borges VF, Baetz TD, Mcspadden T, Fernetich G, Murthy RK, et al. Phase 1 study of ONT-380, a HER2 inhibitor, in patients with HER2 + advanced solid tumors, with an expansion cohort in HER2 + metastatic breast cancer (MBC). Clin Cancer Res 2017;clincanres. 1496.2016.
221. Curigliano, G., Loibl, S., Müller, V., Pivot, X., Wardley, A., Cameron, D., A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2 + unresectable locally advanced or metastatic breast carcinoma (MBC). Ann Oncol, 27(suppl 6), 2016, 312TiP.
222. Borges VF, Ferrario C, Aucoin N, Falkson CI, Khan QJ, Krop IE, et al., editors. Efficacy results of a phase 1 b study of ont-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2 + metastatic breast cancer (MBC), including patients (PTS) with brain metastases. Proceedings of the 2016 American Society of Clinical Oncology (ASCO) annual meeting, Chicago, IL, USA; 2016.
223. Hamilton EP, Yardley DA, Hortobagyi GN, Walker LN, Borges VF, Moulder SL. Phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2 + metastatic breast cancer (MBC). Am Soc Clin Oncol; 2015.
224. Anders CK, Murthy RK, Hamilton EP, Borges VF, Cameron DA, Carey LA, et al. A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2 + unresectable locally advanced or metastatic breast carcinoma (mBC)(HER2CLIMB). Am Soc Clin Oncol; 2017.
225. Duchnowska, R., Szczylik, C., Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev 31:4 (2005), 312–318.
226. Li, Q., Shu, Y., Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cells. Pharm Res 31:1 (2014), 86–96.
227. Hu, J., Ljubimova, J.Y., Inoue, S., Konda, B., Patil, R., Ding, H., et al. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS ONE, 5(4), 2010, e10108.
228. Ningaraj, N.S., Sankpal, U.T., Khaitan, D., Meister, E.A., Vats, T.S., Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model. Cancer Biol Ther 8:20 (2009), 1924–1933.
229. Kinoshita, M., McDannold, N., Jolesz, F.A., Hynynen, K., Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood–brain barrier disruption. Proc Natl Acad Sci 103:31 (2006), 11719–11723.
230. Yu, Y.J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Trans Med, 3(84), 2011 84ra44-84ra44.
231. Demeule, M., Currie, J.C., Bertrand, Y., Che, C., Nguyen, T., Regina, A., et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. J Neurochem 106:4 (2008), 1534–1544.
232. Regina, A., Demeule, M., Tripathy, S., Lord-Dufour, S., Currie, J.-C., Iddir, M., et al. ANG4043, a novel brain-penetrant peptide–mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice. Mol Cancer Ther 14:1 (2015), 129–140.
233. Dowsett, M., Procter, M., McCaskill-Stevens, W., de Azambuja, E., Dafni, U., Rueschoff, J., et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 27:18 (2009), 2962–2969.
234. Paik, S., Kim, C., Wolmark, N., HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358:13 (2008), 1409–1411.
235. Hofmann M, Gross C, Beyser K, Maass J, Rueschoff J, editors. Predictive value of HercepTest IHC and PathVysion FISH data: analysis from a trastazumab phase II monotherapy study. Proc Am Soc Clin Oncol; 2003.
236. Perez E, Romond E, Suman V, Jeong J, Davidson N, Geyer C, et al., editors. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. ASCO annual meeting proceedings; 2007.
237. Hoang, M.P., Sahin, A.A., Ordòñez, N.G., Sneige, N., HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 113:6 (2000), 852–859.
238. Jacobs, T.W., Gown, A.M., Yaziji, H., Barnes, M.J., Schnitt, S.J., Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol, 17(7), 1999, 1974.
239. Roche, P.C., Suman, V.J., Jenkins, R.B., Davidson, N.E., Martino, S., Kaufman, P.A., et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94:11 (2002), 855–857.
240. Perez, E.A., Cortés, J., Gonzalez-Angulo, A.M., Bartlett, J.M., HER2 testing: current status and future directions. Cancer Treat Rev 40:2 (2014), 276–284.
241. Buckley, N.E., Forde, C., McArt, D.G., Boyle, D.P., Mullan, P.B., James, J.A., et al. Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatment. Sci Reports, 6, 2016.
242. Ye, P., Zhang, M., Fan, S., Zhang, T., Fu, H., Su, X., et al. Intra-tumoral heterogeneity of HER2, FGFR2, cMET and ATM in gastric cancer: optimizing personalized healthcare through innovative pathological and statistical analysis. PLoS ONE, 10(11), 2015, e0143207.
243. Ng, C.K., Martelotto, L.G., Gauthier, A., Wen, H.-C., Piscuoglio, S., Lim, R.S., et al. Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. Genome Biol, 16(1), 2015, 107.
244. Vignot, S., Besse, B., André, F., Spano, J.-P., Soria, J.-C., Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. Crit Rev Oncol/Hematol 84:3 (2012), 301–313.
245. Marquez, B.V., Ikotun, O.F., Wright, B., Zheleznyak, A., Richard, P., Lapi, S.E., PET imaging of 89Zr-labeled Pertuzumab in HER2-positive breast cancer xenografts. Can Res, 74(19 Supplement), 2014, 109.
246. Capala, J., Bouchelouche, K., Molecular imaging of HER2-positive breast cancer-a step toward an individualized “Image and Treat” strategy. Curr Opin Oncol, 22(6), 2010, 559.
247. Dijkers, E., Oude Munnink, T., Kosterink, J., Brouwers, A., Jager, P., Jong, Jd., et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87:5 (2010), 586–592.
248. Tamura, K., Kurihara, H., Yonemori, K., Tsuda, H., Suzuki, J., Kono, Y., et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med 54:11 (2013), 1869–1875.
249. Kurihara, H., Hamada, A., Yoshida, M., Shimma, S., Hashimoto, J., Yonemori, K., et al. 64 Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res, 5(1), 2015, 1.
250. Gebhart, G., Lamberts, L., Wimana, Z., Garcia, C., Emonts, P., Ameye, L., et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial. Ann Oncol, 2015 mdv577.
251. Gaykema, S.B., Schröder, C.P., Vitfell-Rasmussen, J., Chua, S., Munnink, T.H.O., Brouwers, A.H., et al. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Clin Cancer Res 20:15 (2014), 3945–3954.
252. Bensch, F., Brouwers, A., Glaudemans, A., de Jong, J., de Vries, E., van de Graaf, W., et al. Abstract OT3-2-01: IMPACT: IMaging PAtients for Cancer drug selecTion–Metastatic breast cancer (MBC). Can Res, 75(9 Supplement), 2015 OT3-2-01-OT3-2-.
253. Sjögren, S., Inganäs, M., Lindgren, A., Holmberg, L., Bergh, J., Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:2 (1998), 462–469.
254. Owens, M.A., Horten, B.C., Da Silva, M.M., HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5:1 (2004), 63–69.
255. Yoshikawa, D., Ojima, H., Iwasaki, M., Hiraoka, N., Kosuge, T., Kasai, S., et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98:2 (2008), 418–425.
256. Harder, J., Waiz, O., Otto, F., Geissler, M., Olschewski, M., Weinhold, B., et al. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 15:36 (2009), 4511–4517.
257. Roa, I., de Toro, G., Schalper, K., de Aretxabala, X., Churi, C., Javle, M., Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer. Gastr Cancer Res: GCR, 7(2), 2014, 42.
258. Javle, M., Churi, C., Kang, H.C., Shroff, R., Janku, F., Surapaneni, R., et al. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol, 8(1), 2015, 1.
259. Pignochino, Y., Sarotto, I., Peraldo-Neia, C., Penachioni, J.Y., Cavalloni, G., Migliardi, G., et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer, 10(1), 2010, 1.
260. Nelson, E.L., HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology. Clin Invest 4:8 (2014), 705–728.
261. Kavanagh, D.O., Chambers, G., O'Grady, L., Barry, K.M., Waldron, R.P., Bennani, F., et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?. BMC Cancer, 9(1), 2009, 1.
262. Pappas, A., Lagoudianakis, E., Seretis, C., Tsiambas, E., Koronakis, N., Toutouzas, K., et al. Clinical role of HER-2/neu expression in colorectal cancer. J BUON 18:1 (2013), 98–104.
263. Seo, A.N., Kwak, Y., Kim, D.-W., Kang, S.-B., Choe, G., Kim, W.H., et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS ONE, 9(5), 2014, e98528.
264. Growdon, W.B., Groeneweg, J., Byron, V., DiGloria, C., Borger, D.R., Tambouret, R., et al. HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant. Gynecol Oncol 137:1 (2015), 160–166.
265. Buza, N., Roque, D.M., Santin, A.D., HER2/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med 138:3 (2014), 343–350.
266. Yano, T., Ohtsu, A., Boku, N., Hashizume, K., Nakanishi, M., Ochiai, A., Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15:1 (2006), 65–71.
267. Gravalos C, Marquez A, Colomer R, Garcia-Carbonero R, Sastre J, Rivera F, et al., editors. Correlation between HER2/neu overexpression/amplification and clinicopathologic parameters in advanced gastric cancer (AGC) patients (pts): a prospective study. ASCO annual meeting proceedings; 2006.
268. Park, D.I., Yun, J.W., Park, J.H., Oh, S.J., Kim, H.J., Cho, Y.K., et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:8 (2006), 1371–1379.
269. Haynik, D.M., Roma, A.A., Prayson, R.A., HER-2/neu expression in glioblastoma multiforme. Appl Immunohistochem Mol Morphol 15:1 (2007), 56–58.
270. Gupta S, Sheikh H, Schneider C, Zhang X, Padmanabhan A, Ali A, editors. HER-2/neu expression in glioblastoma multiforme (GBM). ASCO annual meeting proceedings; 2009.
271. Koka, V., Potti, A., Forseen, S.E., Pervez, H., Fraiman, G.N., Koch, M., et al. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am J Clin Oncol 26:4 (2003), 332–335.
272. Forseen, S.E., Potti, A., Koka, V., Koch, M., Fraiman, G., Levitt, R., Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors. Anticancer Res 22:3 (2001), 1599–1602.
273. Gillison M, Glisson B, O'Leary E, Murphy B, Levine M, Kies M, et al., editors. Phase II trial of trastuzumab (T), paclitaxel (P) and cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous cell carcinoma (HNSCC): response by tumor EGFR and HER2/neu status. ASCO annual meeting proceedings; 2006.
274. Ali, M.A.S., Gunduz, M., Gunduz, E., Tamamura, R., Beder, L.B., Katase, N., et al. Expression and mutation analysis of her2 in head and neck squamous cell carcinoma. Cancer Invest 28:5 (2010), 495–500.
275. Del Campo, J., Hitt, R., Sebastian, P., Carracedo, C., Lokanatha, D., Bourhis, J., et al. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 105:5 (2011), 618–627.
276. Hanken, H., Gaudin, R., Gröbe, A., Fraederich, M., Eichhorn, W., Smeets, R., et al. Her2 expression and gene amplification is rarely detectable in patients with oral squamous cell carcinomas. J Oral Pathol Med 43:4 (2014), 304–308.
277. Pellegrini, C., Falleni, M., Marchetti, A., Cassani, B., Miozzo, M., Buttitta, F., et al. HER-2/Neu alterations in non-small cell lung cancer A comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res 9:10 (2003), 3645–3652.
278. Hirsch, F., Varella-Garcia, M., Franklin, W., Veve, R., Chen, L., Helfrich, B., et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 86:9 (2002), 1449–1456.
279. Heinmöller, P., Gross, C., Beyser, K., Schmidtgen, C., Maass, G., Pedrocchi, M., et al. HER2 status in non-small cell lung cancer results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res 9:14 (2003), 5238–5243.
280. Anglesio, M.S., Kommoss, S., Tolcher, M.C., Clarke, B., Galletta, L., Porter, H., et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol 229:1 (2013), 111–120.
281. McAlpine, J.N., Wiegand, K.C., Vang, R., Ronnett, B.M., Adamiak, A., Köbel, M., et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer, 9(1), 2009, 1.
282. Komoto, M., Nakata, B., Amano, R., Yamada, N., Yashiro, M., Ohira, M., et al. HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci 100:7 (2009), 1243–1247.
283. Stoecklein, N.H., Luebke, A.M., Erbersdobler, A., Knoefel, W.T., Schraut, W., Verde, P.E., et al. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J Clin Oncol 22:23 (2004), 4737–4745.
284. Safran, H., Steinhoff, M., Mangray, S., Rathore, R., King, T.C., Chai, L., et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 24:5 (2001), 496–499.
285. Chou, A., Waddell, N., Cowley, M.J., Gill, A.J., Chang, D.K., Patch, A.-M., et al. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med, 5(8), 2013, 78.
286. Latif, Z., Watters, A., Dunn, I., Grigor, K., Underwood, M., Bartlett, J., HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 89:7 (2003), 1305–1309.
287. Coogan, C.L., Estrada, C.R., Kapur, S., Bloom, K.J., HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 63:4 (2004), 786–790.
288. Ching, C.B., Amin, M.B., Tubbs, R.R., Elson, P., Platt, E., Dreicer, R., et al. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. Mod Pathol 24:8 (2011), 1111–1119.
289. Lae, M., Couturier, J., Oudard, S., Radvanyi, F., Beuzeboc, P., Vieillefond, A., Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 21:4 (2010), 815–819.
290. Gandour-Edwards, R., Lara, P.N., Folkins, A.K., LaSalle, J.M., Beckett, L., Li, Y., et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?. Cancer 95:5 (2002), 1009–1015.
291. Wolff, A.C., Hammond, M.E.H., Hicks, D.G., Dowsett, M., McShane, L.M., Allison, K.H., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:31 (2013), 3997–4013.
292. Bartley, A.N., Washington, M.K., Ventura, C.B., Ismaila, N., Colasacco, C., Benson, A.B., et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma. Am J Clin Pathol, 2016 aqw206.
293. Sequist, L.V., Yang, J.C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:27 (2013), 3327–3334.
294. Miller, V.A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13:5 (2012), 528–538.
295. Katakami, N., Atagi, S., Goto, K., Hida, T., Horai, T., Inoue, A., et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non–small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 31:27 (2013), 3335–3341.
296. Soria, J.-C., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K.H., et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 16:8 (2015), 897–907.
297. Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Rolski, J., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. Can Res, 69(24 Supplement), 2009, 62.
298. Perez, E.A., Romond, E.H., Suman, V.J., Jeong, J.-H., Sledge, G., Geyer, C.E., et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32:33 (2014), 3744–3752.
299. Goldhirsch, A., Gelber, R.D., Piccart-Gebhart, M.J., de Azambuja, E., Procter, M., Suter, T.M., et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382:9897 (2013), 1021–1028.
300. Joensuu, H., Bono, P., Kataja, V., Alanko, T., Kokko, R., Asola, R., et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 27:34 (2009), 5685–5692.
301. Spielmann, M., Roché, H., Delozier, T., Canon, J.-L., Romieu, G., Bourgeois, H., et al. Trastuzumab for patients with axillary-node–positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27:36 (2009), 6129–6134.
302. Gianni, L., Lladó, A., Bianchi, G., Cortes, J., Kellokumpu-Lehtinen, P.-L., Cameron, D.A., et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2–negative metastatic breast cancer. J Clin Oncol 28:7 (2010), 1131–1137.
303. Gianni, L., Eiermann, W., Semiglazov, V., Lluch, A., Tjulandin, S., Zambetti, M., et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 15:6 (2014), 640–647.
304. Untch, M., Rezai, M., Loibl, S., Fasching, P.A., Huober, J., Tesch, H., et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 28:12 (2010), 2024–2031.
305. Buzdar, A.U., Ibrahim, N.K., Francis, D., Booser, D.J., Thomas, E.S., Theriault, R.L., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2–positive operable breast cancer. J Clin Oncol 23:16 (2005), 3676–3685.
306. Buzdar, A.U., Valero, V., Ibrahim, N.K., Francis, D., Broglio, K.R., Theriault, R.L., et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2–positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:1 (2007), 228–233.
307. Steger, G., Greil, R., Lang, A., Rudas, M., Fitzal, F., Mlineritsch, B., et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Ann Oncol 25:2 (2014), 366–371.
308. Gianni, L., Pienkowski, T., Im, Y.-H., Tseng, L.-M., Liu, M.-C., Lluch, A., et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17:6 (2016), 791–800.
309. Nitz U, Gluz O, Christgen M, Grischke E-M, Augustin D, Kummel S, et al., editors. Final analysis of WSG-ADAPT HER2+/HR-trial: efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab +/− weekly paclitaxel in HER2+/HR-early breast cancer (EBC). ASCO annual meeting proceedings; 2016.
310. Andre Robidoux GT, Priya Rastogi, Charles E. Geyer, Catherine A. Azar, James Norman Atkins, Louis Fehrenbacher, et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2 + operable breast cancer: 5-year outcomes of NSABP protocol B-41. J Clin Oncol 2016;34(suppl; abstr 501).
311. Kim AY, Zer C, Williams JC, Press MF, Park JM, editors. Novel murine anti-HER2 monoclonal antibodies to induce apoptosis and regulate miR-21 in breast cancer cell. ASCO annual meeting proceedings; 2013.